TY - JOUR
KW - Public Health, Environmental and Occupational Health
KW - Health(social science)
KW - General Medicine
KW - Community participation
AU - Krentel A
AU - Gyapong M
AU - McFarland D
AU - Ogundahunsi O
AU - Titaley CR
AU - Addiss DG
AB - <jats:title>Abstract</jats:title>
               <jats:p>Since the launch of the Global Programme to Eliminate Lymphatic Filariasis (GPELF) in 2000, more than 910 million people have received preventive chemotherapy for lymphatic filariasis (LF) and many thousands have received care for chronic manifestations of the disease. To achieve this, millions of community drug distributors (CDDs), community members and health personnel have worked together each year to ensure that at-risk communities receive preventive chemotherapy through mass drug administration (MDA). The successes of 20 y of partnership with communities is celebrated, including the application of community-directed treatment, the use of CDDs and integration with other platforms to improve community access to healthcare. Important challenges facing the GPELF moving forward towards 2030 relate to global demographic, financing and programmatic changes. New innovations in research and practice present opportunities to encourage further community partnership to achieve the elimination of LF as a public health problem. We stress the critical need for community ownership in the current Covid-19 pandemic, to counter concerns in relaunching MDA programmes for LF.</jats:p>
BT - International Health
DO - 10.1093/inthealth/ihaa086
IS - Supplement_1
LA - eng
N2 - <jats:title>Abstract</jats:title>
               <jats:p>Since the launch of the Global Programme to Eliminate Lymphatic Filariasis (GPELF) in 2000, more than 910 million people have received preventive chemotherapy for lymphatic filariasis (LF) and many thousands have received care for chronic manifestations of the disease. To achieve this, millions of community drug distributors (CDDs), community members and health personnel have worked together each year to ensure that at-risk communities receive preventive chemotherapy through mass drug administration (MDA). The successes of 20 y of partnership with communities is celebrated, including the application of community-directed treatment, the use of CDDs and integration with other platforms to improve community access to healthcare. Important challenges facing the GPELF moving forward towards 2030 relate to global demographic, financing and programmatic changes. New innovations in research and practice present opportunities to encourage further community partnership to achieve the elimination of LF as a public health problem. We stress the critical need for community ownership in the current Covid-19 pandemic, to counter concerns in relaunching MDA programmes for LF.</jats:p>
PB - Oxford University Press (OUP)
PY - 2020
SP - S55
EP - S59
T2 - International Health
TI - Keeping communities at the centre of efforts to eliminate lymphatic filariasis: learning from the past to reach a future free of lymphatic filariasis
UR - https://academic.oup.com/inthealth/article-pdf/13/Supplement_1/S55/35056137/ihaa086.pdf
VL - 13
SN - 1876-3413, 1876-3405
ER -